Indian bankers that specialize in selling corporate debt securities are asking the financial regulator for permission to borrow funds against bonds, according to people familiar with the matter, as authorities themselves seek to deepen local capital markets. The intermediaries known as merchant bankers in India say the move would give them more financial flexibility to underwrite debt issuances, t...
Indian bankers that specialize in selling corporate debt securities are asking the financial regulator for permission to borrow funds against bonds, according to people familiar with the matter, as authorities themselves seek to deepen local capital markets. The intermediaries known as merchant bankers in India say the move would give them more financial flexibility to underwrite debt issuances, the people said, asking not to be named discussing private matters. Currently, the amount they can underwrite is limited by their net worth, and they are barred from tapping the bond market for this activity. In recent meetings with the Securities and Exchange Board of India , merchant bankers also sought approval to raise funds via banks, non-banking financiers and the capital markets, the people said. These changes would enable them to better manage bonds on their books if a debt sale fails to draw sufficient demand. It would also bring them on par with primary dealers in India’s sovereign bond market, who have greater flexibility to manage such risks, they said. The discussions underscore the challenges India faces in its push to deepen its 58-trillion-rupee ($638 billion) corporate bond market, which is crucial to support the country’s growing infrastructure financing needs. The market is plagued by low liquidity and elevated transaction costs, and most bond sales are dominated by highly-rated companies. Read More: India Proposes New Incentives to Boost Municipal Bond Market A spokesperson for SEBI didn’t respond to an email seeking comment. Brokers and merchant bankers have also asked the regulator for an anonymous trading platform for corporate bonds, which they say would help improve price discovery, the people said. They have urged SEBI to treat debt merchant bankers separately from their equity-focused counterparts when drawing up the regulatory framework, they said.
Reinsurance Group of America ( RGA ) priced a new debt offering of $400M 6.375% fixed-rate reset subordinated debentures due 2056. The 2056 debentures have a maturity date of September 15, 2056, an issue price of 100% and feature a fixed-rate coupon of 6.375%, payable semiannually in arrears. The company expects to use the net proceeds from the offering for general corporate purposes, which may in...
Reinsurance Group of America ( RGA ) priced a new debt offering of $400M 6.375% fixed-rate reset subordinated debentures due 2056. The 2056 debentures have a maturity date of September 15, 2056, an issue price of 100% and feature a fixed-rate coupon of 6.375%, payable semiannually in arrears. The company expects to use the net proceeds from the offering for general corporate purposes, which may include refinancing debt obligations. The offering closes around March 3, 2026. More on Reinsurance Group of America Reinsurance Group of America, Incorporated (RGA) Q4 2025 Earnings Call Transcript Reinsurance Group of America, Incorporated 2025 Q4 - Results - Earnings Call Presentation Reinsurance Group Of America: Lock In 2% 'Alpha' With The Baby Bonds RGA reiterates 8%-10% EPS growth target and signals exit from group health care business amid strong Q4 results Seeking Alpha’s Quant Rating on Reinsurance Group of America
GSK Plc agreed to buy 35Pharma Inc., a biotech with an early-stage high blood pressure drug, as the UK pharmaceutical company expands into cardiovascular medicine. GSK will buy the closely held Canadian firm for $950 million in cash, it said in a statement Wednesday. The deal marks a shift for GSK, which has a small pipeline of drugs for diseases affecting the heart and metabolic systems. New Chie...
GSK Plc agreed to buy 35Pharma Inc., a biotech with an early-stage high blood pressure drug, as the UK pharmaceutical company expands into cardiovascular medicine. GSK will buy the closely held Canadian firm for $950 million in cash, it said in a statement Wednesday. The deal marks a shift for GSK, which has a small pipeline of drugs for diseases affecting the heart and metabolic systems. New Chief Executive Officer Luke Miels is under pressure to increase GSK’s new medicines as he looks to offset the patent expiry of a blockbuster HIV drug.